Market research reports, consulting: Global Market Insights Inc.
We use cookies to enhance user experience. (Privacy Policy)

Primary Biliary Cholangitis Therapeutics Market Trends

Report ID: GMI10014
   |
Published Date: June 2024
 | 
Report Format: PDF

Download free sample

Primary Biliary Cholangitis Therapeutics Market Trends

  • The rise in the prevalence of primary biliary cholangitis (PBC) significantly propels the growth of the PBC therapeutics market by increasing the number of patients requiring treatment and driving demand for innovative therapies. In addition, as the awareness and diagnosis of PBC improve, more patients are identified and treated, which in turn fuels the market for therapeutic solutions.
     
  • For instance, a study published in the journal of National Institute of Health in August 2022 reported that the global prevalence of PBC is in the range from 1.9 to 40.2 per 100 000 individuals. Diagnosis is typically made between 55 and 65 years of age, and women are disproportionately affected with a female-to-male ratio of up to 9:1. Thus, as the number of diagnosed cases grows, the demand for effective treatment options also escalates.
     
  • Further, patients diagnosed with PBC require long-term management to slow disease progression and mitigate symptoms, necessitating a steady and growing market for PBC therapeutics.
     
  • Moreover, pharmaceutical companies are intensely involved in research and development activities to introduce new and improved therapies. The expansion of the patient population creates a lucrative market for both existing drugs and novel treatments, thereby fostering innovation and competition within the industry.
Authors: Mariam Faizullabhoy , Gauri Wani
Frequently Asked Question(FAQ) :
Who are the leading primary biliary cholangitis (PBC) therapeutics market players?
Abbott Laboratories, Arlak Biotech Pvt. Ltd, Cadila Pharmaceuticals, Drag Pharma, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Ipsen, Leeford Healthcare Limited, Lupin, Sun Pharmaceuticals Ltd., Viatris, Inc. (Mylan N.V.), and Vivaldis.
How big is the North America primary biliary cholangitis therapeutics market?
Why is the demand for PBC therapeutics rising among humans?
What is the size of the primary biliary cholangitis therapeutics market?
Primary Biliary Cholangitis Therapeutics Market Scope
Related Reports
    Authors: Mariam Faizullabhoy , Gauri Wani
    Buy Now
    $4,123 $4,850
    15% off
    $4,280 $5,350
    20% off
    $5,845 $8,350
    30% off
        Buy now
    Premium Report Details

    Base Year: 2023

    Companies covered: 12

    Tables & Figures: 112

    Countries covered: 22

    Pages: 150

    Download Free Sample

    Top